Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Randomised controlled trials

Escitalopram does not improve outcomes for depressed patients with heart failure

Researchers recorded death or hospitalisation rate of 63% in patients taking escitalopram, and 64% in those given placebo.

Molecular structure of escitalopram

Source: Shutterstock.com

The antidepressant escitalopram (pictured) did not improve depression or improve mortality in patients with major depression and heart failure

Depression is common in patients with cardiovascular disease. Also, having depression increases the chance of death and hospitalisation in patients with heart failure, raising the question of whether antidepressants might improve outcomes. 

Researchers in Germany assigned 372 patients with systolic heart failure and major depression to either escitalopram – a selective serotonin reuptake inhibitor (SSRI) – or placebo, for 24 months. 

Death or hospitalisation was recorded in 63% of patients given escitalopram and in 64% given placebo after 18.4 months and 18.7 months, respectively. 

On the Montgomery Åsberg Depression Rating Scale, scores dropped after 12 weeks from 20.2 at baseline to 11.2 in the escitalopram group, and from 21.4 to 12.5 in the placebo group. 

The authors, writing in JAMA (online, 28 June 2016)[1], say that the findings do not support the use of escitalopram in depressed patients with systolic heart failure.

Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2016.20201408

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Molecular structure of escitalopram

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.